secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001477932-25-008182
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx Q3 revenue up 32% to $0.6M; signs deals with Werfen and Hologic
--------------------------------------------------------------------------

- Revenue $0.6M (+32% YoY); net loss down 8% YoY; operating expenses down 10% YoY.
- Net cash used in ops $3.6M (-33% YoY); post-quarter raised $6.1M net from public offering.
- Signed Research License and Option Agreement for APS with Werfen; Co-Marketing Agreement with Hologic.
- In discussions with ~10 leading diagnostic/liquid biopsy companies for further licensing deals.
- Anticipates peer-reviewed publications on Nu.Q platform and Capture-Seq technology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793225008182/0001477932-25-008182-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793225008182/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-25-008182

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer